| Literature DB >> 32024303 |
Abstract
Dehydration risk increases with frailty and functional dependency, but a limited number of studies have evaluated this association in hospitalized geriatric patients. This cross-sectional study aimed to assess the prevalence and determinants of dehydration in patients admitted to the geriatric ward. Dehydration was diagnosed when calculated osmolarity was above 295 mMol/L. Logistic regression analyses (direct and stepwise backward) were used to assess determinants of impending dehydration. 358 of 416 hospitalized patients (86.1%) were included: 274 (76.5%) women, and 309 (86.4%) 75+ year-old. Dehydration was diagnosed in 209 (58.4%) cases. Significantly higher odds for impending dehydration were observed only for chronic kidney disease with trends for diabetes and procognitive medication when controlling for several health, biochemical, and nutritional parameters and medications. After adjusting for "dementia" the negative effect of "taking procognitive medications" became a significant one. Chronic kidney disease, diabetes, taking procognitive medications and hypertension were the main variables for the outcome prediction according to the stepwise backward regression analysis. This may indicate an additional benefit of reducing the risk of dehydration when using procognitive drugs in older patients with dementia.Entities:
Keywords: acetylcholine esterase inhibitor; chronic renal disease; electrolyte; fluid intake; frailty; geriatric inpatients; impending dehydration; osmolyte; procognitive medications; water intake
Mesh:
Substances:
Year: 2020 PMID: 32024303 PMCID: PMC7071250 DOI: 10.3390/nu12020398
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart of patient enrollment.
Characteristics of participants by dehydration status- sociodemographic, health, biochemical parameters and medications.
| All | Dehydration+ | Dehydration- |
| Missing Values | |
|---|---|---|---|---|---|
| 358 (100.0) | 209 (58.4) | 149 (41.6) | |||
| Sociodemographic parameters | |||||
| Age (y), Mdn (IQR) | 82 (78–86) | 82 (78–86) | 82 (77–86) | 0.33 | |
| Age (75+), | 309 (86.3) | 185 (88.5) | 124 (83.2) | 0.16 | - |
| Sex (F), | 274 (76.5) | 161 (77.0) | 113 (75.8) | 0.80 | - |
| Residence (rural), | 77 (21.5) | 45 (21.5) | 32 (21.59) | 1.00 | - |
| Living in long term care, | 11 (3.1) | 7 (3.3) | 4 (2.7) | 1.0 | - |
| Living alone, | 105 (30.3) | 64 (31.7) | 41 (28.3) | 0.55 | 11 |
| Health parameters | |||||
| Hospitalizations in the last year, | 98 (27.6) | 55 (26.6) | 43 (29.1) | 0.63 | 3 |
| Chronic diseases, Mdn (IQR) | 5.0 (3.0–6.0) | 5.0 (4.0–6.0) | 4.0 (3.0–6.0) |
| |
| Multimorbidity, | 210 (58.7) | 134 (64.1) | 76 (51.0) |
| - |
| Parkinson disease, | 51 (14.2) | 29 (13.9) | 22 (14.8) | 0.88 | - |
| Dementia, | 122 (34.1) | 69 (33.0) | 53 (35.6) | 0.65 | - |
| Depression, | 154 (55.8) | 87 (53.0) | 67 (59.8) | 0.27 | 82 |
| Ischemic heart disease, | 191 (53.4) | 121 (57.9) | 70 (47.0) | 0.05 | - |
| Chronic cardiac failure, | 141 (39.4) | 90 (43.1) | 51 (34.2) | 0.10 | - |
| NYHA class I/II, | 70 (49.6) | 44 (48.9) | 26 (51.0) | 0.86 | |
| NYHA class III/IV, | 71 (50.4) | 46 (51.1) | 25 (49.0) | ||
| Atrial fibrillation, | 88 (24.6) | 52 (24.9) | 36 (24.2) | 0.90 | - |
| Myocardial infarction, | 35 (9.8) | 24 (11.5) | 11 (7.4) | 0.21 | - |
| Peripheral arterial disease, | 57 (15.9) | 32 (15.3) | 25 (16.8) | 0.77 | - |
| Diabetes, | 108 (30.2) | 76 (36.4) | 32 (21.5) |
| - |
| Hypertension, | 278 (77.7) | 176 (84.2) | 102 (68.5) |
| - |
| Stroke/ TIA, | 52 (14.5) | 30 (14.4) | 22 (14.8) | 1.00 | - |
| Neoplasm, | 31 (8.7) | 16 (7.7) | 15 (10.1) | 0.45 | - |
| Osteoarthritis, | 277 (77.4) | 164 (78.5) | 113 (75.8) | 0.61 | - |
| Osteoporosis, | 56 (15.6) | 30 (14.4) | 26 (17.4) | 0.46 | - |
| Chronic kidney disease, | 191 (53.4) | 133 (63.6) | 58 (38.9) |
| - |
| Urinary incontinence, | 171 (47.9) | 102 (48.8) | 69 (46.6) | 0.75 | 1 |
| Systolic BP, mmHg, Mdn (IQR) | 130 (120–140) | 130 (120–140) | 130 (120–140) | 0.28 | 3 |
| Diastolic BP, mmHg, Mdn (IQR) | 70 (60–80) | 70 (60–80) | 70 (60–80) | 0.55 | 3 |
| Orthostatic hypotension, | 50 (16.1) | 27 (15.0 | 23 (17.7) | 0.54 | 48 |
| Biochemical parameters | |||||
| Osmolarity, mMol/L, Mdn (IQR) | 296.5 (292.2–299.6) | 298.9 (296.9–301.6) | 291.1 (287.3–293.3) |
| - |
| Serum sodium, mmol/L, Mdn (IQR) | 140.0 (138.0–141.0) | 141.0 (140.0–142.0) | 138.0 (136.0–139.0) |
| - |
| Hyponatremia, | 24 (6.7) | 4 (1.9) | 20 (13.4) |
| - |
| Serum potassium, mmol/L, M(SD) | 4.43 (0.46) | 4.50 (0.46) | 4.33 (0.44) |
| - |
| Serum urea, mmol/L, Mdn (IQR) | 6.9 (5.5–8.8) | 7.8 (6.2–9.9) | 5.8 (4.9–7.3) |
| - |
| Fasting glucose, mmol/L, Mdn (IQR) | 5.5 (5.0–6.3) | 5.6 (5.2–6.7) | 5.3 (4.9–5.8) |
| - |
| >7.8mmol/L, | 43 (12.0) | 36 (17.2) | 7 (4.7) |
| |
| >10mmol/L, | 12 (3.6) | 10 (4.9) | 2 (1.6) | 0.14 | |
| Serum calcium, mmol/L, M (SD) | 1.14 (0.07) | 1.15 (0.07) | 1.13 (0.06) | 0.14 | 84 |
| eGFR, ml/min/1.73m2, M (SD) | 57.8 (17.1) | 58.2 (16.8) | 58.4 (16.7) | 0.91 | 4 |
| Serum creatinine, mmol/L, Mdn (IQR) | 86.2 (74.3–107.2) | 91.05 (77.8–115.8) | 78.7 (69.8–96.4) |
| 4 |
| Hemoglobin, mmol/L, M (SD) | 7.76 (1.08) | 7.75 (1.08) | 7.79 (1.08) | 0.70 | 3 |
| Anemia, | 158 (44.5) | 92 (44.7) | 66 (44.3) | 1.0 | 3 |
| Medications | |||||
| Number of medications, Mdn (IQR) | 7.0 (5.0–9.0) | 7.0 (5.0–10.0) | 7.0 (4.0–9.0) |
| 8 |
| Polypharmacy, | 275 (78.6) | 172 (83.5) | 103 (71.5) |
| 8 |
| Alfa1-blockers, | 21 (6.0) | 13 (6.3) | 8 (5.6) | 0.82 | 9 |
| Neuroleptics, | 63 (18.1) | 34 (16.6) | 29 (20.1) | 0.40 | 9 |
| ACE-I/ ARB, | 219 (62.8) | 138 (67.3) | 81 (56.3) |
| 9 |
| Procognitive medications, | 45 (12.9) | 20 (9.8) | 25 (17.4) | 0.05 | 9 |
| AChE-I, | 40 (11.5) | 18 (8.8) | 22 (15.3) | 0.09 | 9 |
| Memantine, | 13 (3.7) | 4 (2.0) | 9 (6.3) |
| 9 |
| Donepezil, | 26 (7.4) | 13 (6.3) | 13 (9.0) | 0.41 | 9 |
| Rivastigmine, | 14 (4.0) | 5 (2.4) | 9 (6.3) | 0.097 | 9 |
| Calcium channel blockers, | 96 (27.5) | 58 (28.3) | 38 (26.4) | 0.72 | 9 |
| Beta-blockers, | 223 (63.9) | 141 (68.8) | 82 (56.9) |
| 9 |
| Digoxin, | 27 (7.7) | 17 (8.3) | 10 (6.9) | 0.69 | 9 |
| Diuretics, | 166 (47.6) | 110 (53.7) | 56 (38.9) |
| 9 |
| Lipid lowering drugs, | 117 (33.5) | 78 (38.0) | 39 (27.1) |
| 9 |
| Benzodiazepines, | 41 (11.7) | 24 (11.7) | 17 (11.8) | 1.00 | 8 |
| SSRI, | 97 (27.8) | 49 (23.9) | 48 (33.3) | 0.07 | 9 |
| NSAIDs, | 21 (6.0) | 14 (6.8) | 7 (4.9) | 0.50 | 9 |
1 – a t-test for independent samples or a Mann–Whitney test (continuous or interval variables) and χ2 test (categorical variables) were used to compare participants categorized according to dehydration status. In all the analyses, a two-tailed p value of less than 0.05 was regarded as significant. ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; AChE-I, acetylcholinesterase inhibitor; BP, blood pressure; eGFR, glomerular filtration rate; F, female; IQR, interquartile range; M, mean value; Mdn, median value; n, number of cases; NSAIDs, non-steroidal anti-inflammatory drugs; NYHA, New York Heart Association; SSRI, selective serotonin reuptake inhibitors; SD, standard deviation; TIA, transient ischemic attack; y, years. Bold signifies a statistically significant value.
Characteristics of participants by dehydration status- functional and nutritional parameters.
| All | Dehydration+ | Dehydration- |
| Missing Values | |
|---|---|---|---|---|---|
| 358 (100.0) | 209 (58.4) | 149 (41.6) | |||
| Functional parameters | |||||
| Barthel Index, Mdn (IQR) | 90 (70–100) | 90 (70–100) | 90 (65–100) | 0.48 | 2 |
| IADL, Mdn (IQR) | 7.0 (2.0–11.0) | 7.0 (2.0–11.0) | 7.0 (1.75–11.0) | 0.55 | 6 |
| AMTS, Mdn (IQR) | 8.0 (6.0–9.0) | 8.0 (6.0–9.0) | 8.0 (6.0–9.0) | 0.88 | 26 |
| GDS, Mdn (IQR) | 6.5 (3.0–10.0) | 6.0 (3.0–10.0) | 7.0 (4.0–10.0) | 0.32 | 38 |
| Handgrip, kg, M (SD) | 18.9 (7.4) | 18.93 (7.5) | 18.97 (7.3) | 0.96 | 55 |
| man ( | 26.3 (8.6) | 26.8 (9.3) | 25.7 (7.8) | 0.61 | 16 |
| woman ( | 16.8 (5.5) | 16.9 (5.3) | 16.7 (5.7) | 0.86 | 39 |
| Sarcopenia, | 140 (46.2) | 80 (46.0) | 60 (46.5) | 1.0 | 55 |
| Gait speed, m/s, M (SD) | 0.68 (0.34) | 0.60 (0.37) | 0.69 (0.35) | 0.65 | 88 |
| Gait speed ≤ 0.8 m/s, | 176 (65.2) | 110 (69.2) | 66 (59.5) | 0.12 | 88 |
| POMA score, Mdn (IQR) | 23.0 (17.3–28.0) | 23.0 (18.0–28.0) | 23.0 (16.8–28.0) | 0.92 | 78 |
| POMA < 19 points, | 81 (28.9) | 47 (29.0) | 34 (28.8) | 1.00 | 78 |
| TUG, s, Mdn (IQR) | 17.4 (12.0–28.1) | 18.9 (12.4–28.0) | 16.6 (11.7–28.4) | 0.68 | 97 |
| TUG ≥ 20 s, | 110 (42.1) | 69 (45.1) | 41 (38.0) | 0.26 | 97 |
| Falls in the last 12 months, | 144 (46.6) | 80 (44.9) | 64 (48.9) | 0.56 | 49 |
| CFS, Mdn (IQR) | 5.0 (4.0–6.0) | 5.0 (4.0–6.0) | 5.0 (4.0–5.5) | 0.69 | - |
| Severe frailty, | 91 (25.4) | 54 (25.8) | 37 (24.8) | 0.90 | - |
| Norton scale score, Mdn (IQR) | 17.0 (15.0–19.0) | 17.0 (15.0–19.0) | 17.0 (15.0–19.0) | 0.64 | 2 |
| Nutritional parameters | |||||
| BMI, kg/m2, M (SD) | 29.0 (6.0) | 29.8 (6.2) | 28.1 (5.6) |
| 55 |
| BMI < 24 kg/m2, | 59 (19.5) | 32 (18.3) | 27 (21.1) | 0.56 | 55 |
| BMI > 30 kg/m2, | 124 (40.9) | 81 (46.3) | 43 (33.6) |
| 55 |
| Albumin, g/L, M (SD) | 38.9 (3.8) | 39.2 (3.7) | 38.5 (4.0) | 0.11 | 11 |
| Albumin < 35 g/L | 54 (15.6) | 29 (14.5) | 25 (17.0) | 0.55 | 11 |
| MNA-SF, Mdn (IQR) | 11.0 (9.0–13.0) | 12.0 (9.0–13.0) | 11.0 (9.0–13.0) | 0.26 | 9 |
| MNA-SF score <8, n (%) | 62 (17.8) | 34 (16.7) | 28 (19.2) | 0.57 | 9 |
| WHR, Mdn (IQR) | 0.91 (0.86–0.95) | 0.91 (0.85–0.96) | 0.91 (0.87–0.95) | 0.63 | 44 |
| Waist circumference, m, Mdn (IQR) | 0.97 (0.87–1.07) | 0.98 (0.87–1.09) | 0.94 (0.85–1.04) |
| 37 |
| Abdominal obesity, | 271 (84.4) | 166 (87.4) | 105 (80.2) | 0.09 | 37 |
1 –a t-test for independent samples or Mann–Whitney test (continuous or interval variables) and χ2 test (categorical variables) were used to compare participants categorized according to dehydration status. In all analyses, a two-tailed p value of less than 0.05 was regarded as significant. AMTS, Abbreviated Mental Test Score; BMI, body mass index; CFS, 7-point Clinical Frailty Scale level; GDS,15 items Geriatric Depression Scale; IADL, instrumental activities of daily living; IQR, interquartile range; M, mean value; Mdn, median value; MNA-SF, Mini Nutritional Assessment-Short Form; n, number of cases; POMA, Performance Oriented Mobility Assessment test; TUG, Timed Up and Go test; SD, standard deviation; WHR, waist-hip ratio. Bold signifies a statistically significant value.
Determinants of “dehydration +” status- direct multivariable logistic regression models.
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| |
|---|---|---|---|---|---|---|---|---|---|
| MODEL 1 | MODEL 2 | MODEL 3 | |||||||
| Chronic kidney disease | 2.40 | 1.3–4.1 |
| 2.30 | 1.3–4.0 |
| 2.27 | 1.3–4.1 |
|
| Diabetes mellitus | 1.80 | 0.96–3.4 | 0.07 | 1.75 | 0.9–3.3 | 0.08 | 1.75 | 0.9–3.3 | 0.09 |
| Procognitive medications | 0.48 | 0.2–1.1 | 0.08 | 0.37 | 0.1–0.99 |
| 0.37 | 0.14–0.99 |
|
| Hypertension | 1.63 | 0.8–3.5 | 0.20 | 1.62 | 0.8–3.4 | 0.21 | 1.63 | 0.8–3.5 | 0.20 |
| Ischemic heart disease | 1.12 | 0.6–1.99 | 0.69 | 1.12 | 0.6–1.99 | 0.70 | 1.11 | 0.6–1.98 | 0.72 |
| Chronic cardiac failure | 0.90 | 0.5–1.6 | 0.73 | 0.93 | 0.5–1.7 | 0.81 | 0.92 | 0.5–1.7 | 0.78 |
| Beta-blockers | 1.20 | 0.7–2.3 | 0.49 | 1.20 | 0.6–2.2 | 0.56 | 1.21 | 0.6–2.3 | 0.56 |
| Statins | 1.02 | 0.6–1.8 | 0.95 | 1.02 | 0.6–1.8 | 0.95 | 1.02 | 0.6–1.8 | 0.96 |
| SSRI | 0.80 | 0.4–1.5 | 0.50 | 0.79 | 0.4–1.5 | 0.49 | 0.80 | 0.4–1.5 | 0.50 |
| Diuretics | 1.17 | 0.6–2.1 | 0.61 | 1.17 | 0.6–2.1 | 0.60 | 1.17 | 0.6–2.1 | 0.60 |
| ACE-I or ARB | 0.91 | 0.5–1.8 | 0.78 | 0.93 | 0.5–1.8 | 0.83 | 0.93 | 0.5–1.8 | 0.84 |
| Polypharmacy | 1.12 | 0.5–2.4 | 0.78 | 1.16 | 0.5–2.5 | 0.72 | 1.16 | 0.5–2.5 | 0.72 |
| Abdominal obesity | 0.95 | 0.4–2.1 | 0.90 | 1.005 | 0.5–2.2 | 0.99 | 1.02 | 0.5–2.3 | 0.96 |
| BMI > 30 kg/m2 | 1.13 | 0.6–2.1 | 0.69 | 1.12 | 0.6–2.0 | 0.72 | 1.13 | 0.6–2.1 | 0.71 |
| Dementia | 1.41 | 0.7–2.8 | 0.33 | 1.39 | 0.7–2.8 | 0.36 | |||
| Age | 1.01 | 0.96–1.05 | 0.84 | ||||||
| Gender | 1.05 | 0.5–2.1 | 0.88 | ||||||
ACE-I, angiotensin converting enzyme inhibitor; ARB-, angiotensin II receptor blocker; BMI, body mass index; CI, confidence interval; OR, odds ratio; SSRI, selective serotonin reuptake inhibitor. p value of less than 0.05 was regarded as significant. Bold signifies a statistically significant value.
Determinants of “dehydration+” status- stepwise backward multivariable logistic regression analysis.
| OR | 95% CI |
| |
|---|---|---|---|
| MODEL 4 | |||
| Chronic kidney disease | 2.53 | 1.51–4.27 |
|
| Diabetes mellitus | 1.9 | 1.04–3.44 |
|
| Procognitive medications | 0.42 | 0.20–0.88 |
|
| Hypertension | 1.75 | 0.91–3.34 | 0.09 |
Variables included in the analysis: hypertension, ischemic heart disease, cardiac heart failure, diabetes/ prediabetes, chronic kidney disease, taking procognitive medications, beta-blockers, statins, selective serotonin reuptake inhibitors (SSRI), diuretics, ACE-I or ARB, abdominal obesity, BMI > 30 kg/m2, polypharmacy, dementia, age, and gender. p value of less than 0.05 was regarded as significant. Bold signifies a statistically significant value.